trial · primary record
ASTX727 + retifanlimab
Merkel Cell Carcinoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 31 |
| Primary completion | 2031-05 |
| Primary endpoint | Percentage of subjects with treatment-emergent adverse events |
| Registry ID | NCT07472322 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:42:03.480Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07472322
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.